Calibr-Skaggs Advances CLF065, a Regenerative GLP-2 Therapy, into Two Phase 2 IBD Studies
AI Briefing
- • Calibr-Skaggs enrolls first patient in Phase 2 study of CLF065 for chronic pouchitis.
- • CLF065, a GLP-2 receptor agonist, advances to Phase 2 IBD studies.
- • Calibr-Skaggs files Investigational New Drug application for CLF065.
Source Summary
LA JOLLA, Calif.--(BUSINESS WIRE)--The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development arm of Scripps Research, today announced two milestones in the clinical advancement of CLF065, its potential best-in-class, long-acting glucagon-like peptide-2 (GLP-2) receptor agonist in development for inflammatory bowel diseases (IBD). Calibr-Skaggs has enrolled the first patient in its Phase 2 study of CLF065 in chronic pouchitis and has filed an Investigational New Drug (
Advertisement